ATE444964T1 - 5-pyridinyl-1-azabicycloä3.2.1üoctan-derivate, herstellungsverfahren und deren verwendung für therapeutika - Google Patents

5-pyridinyl-1-azabicycloä3.2.1üoctan-derivate, herstellungsverfahren und deren verwendung für therapeutika

Info

Publication number
ATE444964T1
ATE444964T1 AT06794298T AT06794298T ATE444964T1 AT E444964 T1 ATE444964 T1 AT E444964T1 AT 06794298 T AT06794298 T AT 06794298T AT 06794298 T AT06794298 T AT 06794298T AT E444964 T1 ATE444964 T1 AT E444964T1
Authority
AT
Austria
Prior art keywords
therapeutics
pyridinyl
derivatives
production process
compounds
Prior art date
Application number
AT06794298T
Other languages
English (en)
Inventor
Frederic Galli
Odile Leclerc
Alistair Lochead
Julien Vache
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36273387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE444964(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE444964T1 publication Critical patent/ATE444964T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06794298T 2005-08-12 2006-08-07 5-pyridinyl-1-azabicycloä3.2.1üoctan-derivate, herstellungsverfahren und deren verwendung für therapeutika ATE444964T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508528A FR2889701B1 (fr) 2005-08-12 2005-08-12 Derives de 5-pyridinyl-1-azabicyclo[3.2.1]octane, leur preparation en therapeutique.
PCT/FR2006/001912 WO2007020344A1 (fr) 2005-08-12 2006-08-07 DÉRIVÉS DE δ-PYRIDINYL-i-AZABICYCLO[3.2.1]OCTANE, A LEUR PRÉPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE

Publications (1)

Publication Number Publication Date
ATE444964T1 true ATE444964T1 (de) 2009-10-15

Family

ID=36273387

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06794298T ATE444964T1 (de) 2005-08-12 2006-08-07 5-pyridinyl-1-azabicycloä3.2.1üoctan-derivate, herstellungsverfahren und deren verwendung für therapeutika

Country Status (41)

Country Link
US (2) US7863290B2 (de)
EP (1) EP1915375B1 (de)
JP (1) JP5164841B2 (de)
KR (1) KR101299339B1 (de)
CN (1) CN101238125B (de)
AT (1) ATE444964T1 (de)
AU (1) AU2006281341B2 (de)
BR (1) BRPI0614623A2 (de)
CA (1) CA2617828C (de)
CR (1) CR9625A (de)
CY (1) CY1109717T1 (de)
DE (1) DE602006009668D1 (de)
DK (1) DK1915375T3 (de)
DO (1) DOP2006000180A (de)
EA (1) EA014023B1 (de)
EC (1) ECSP088170A (de)
ES (1) ES2332472T3 (de)
FR (1) FR2889701B1 (de)
GT (1) GT200600368A (de)
HK (1) HK1120788A1 (de)
HN (1) HN2008000090A (de)
HR (1) HRP20090677T1 (de)
IL (1) IL188796A (de)
JO (1) JO2583B1 (de)
MA (1) MA30200B1 (de)
ME (1) ME01750B (de)
MX (1) MX2008001968A (de)
MY (1) MY147846A (de)
NO (1) NO20081151L (de)
NZ (1) NZ565149A (de)
PE (1) PE20070339A1 (de)
PL (1) PL1915375T3 (de)
PT (1) PT1915375E (de)
RS (1) RS51068B (de)
SI (1) SI1915375T1 (de)
TN (1) TNSN07472A1 (de)
TW (1) TWI324158B (de)
UA (1) UA92917C2 (de)
UY (1) UY29744A1 (de)
WO (1) WO2007020344A1 (de)
ZA (1) ZA200800958B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912404B1 (fr) * 2007-02-09 2009-04-10 Sanofi Aventis Sa Derives d'azabicycloalkane,leur preparation et leur application en therapeutique.
GB0817424D0 (en) 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
JP2017114765A (ja) * 2014-04-25 2017-06-29 大正製薬株式会社 トリアゾリルで置換されたヘテロアリール化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
EP0664293A1 (de) * 1993-12-24 1995-07-26 Duphar International Research B.V 2-Phenyl-7-azabicycloheptane und 6-Phenyl-8-azabicyclo-octane
CA2289574C (en) * 1997-05-30 2007-04-24 Neurosearch A/S 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
FR2834511B1 (fr) * 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
CA2617828A1 (fr) 2007-02-22
GT200600368A (es) 2007-07-06
FR2889701A1 (fr) 2007-02-16
ECSP088170A (es) 2008-03-26
CA2617828C (fr) 2014-03-11
MA30200B1 (fr) 2009-02-02
UA92917C2 (uk) 2010-12-27
EP1915375A1 (de) 2008-04-30
IL188796A (en) 2012-09-24
US20110077264A1 (en) 2011-03-31
DK1915375T3 (da) 2010-02-15
FR2889701B1 (fr) 2007-10-05
NZ565149A (en) 2011-05-27
HK1120788A1 (de) 2009-04-09
CN101238125B (zh) 2012-07-04
IL188796A0 (en) 2008-08-07
HN2008000090A (es) 2010-08-19
PL1915375T3 (pl) 2010-03-31
KR20080033378A (ko) 2008-04-16
CN101238125A (zh) 2008-08-06
TWI324158B (en) 2010-05-01
JP5164841B2 (ja) 2013-03-21
RS51068B (sr) 2010-10-31
MX2008001968A (es) 2008-03-26
DE602006009668D1 (de) 2009-11-19
PT1915375E (pt) 2009-11-26
US7863290B2 (en) 2011-01-04
HRP20090677T1 (hr) 2010-01-31
CR9625A (es) 2008-04-10
JP2009505971A (ja) 2009-02-12
MY147846A (en) 2013-01-31
DOP2006000180A (es) 2007-02-28
NO20081151L (no) 2008-05-13
TNSN07472A1 (en) 2009-03-17
EA014023B1 (ru) 2010-08-30
KR101299339B1 (ko) 2013-08-26
WO2007020344A1 (fr) 2007-02-22
PE20070339A1 (es) 2007-04-18
US20080146608A1 (en) 2008-06-19
CY1109717T1 (el) 2014-08-13
US8541440B2 (en) 2013-09-24
ZA200800958B (en) 2009-04-29
ES2332472T3 (es) 2010-02-05
AU2006281341A1 (en) 2007-02-22
ME01750B (me) 2010-10-31
UY29744A1 (es) 2007-03-30
BRPI0614623A2 (pt) 2011-04-12
JO2583B1 (en) 2011-02-27
TW200740810A (en) 2007-11-01
EA200800575A1 (ru) 2008-06-30
SI1915375T1 (sl) 2010-01-29
EP1915375B1 (de) 2009-10-07
AU2006281341B2 (en) 2012-04-19

Similar Documents

Publication Publication Date Title
TW200640859A (en) Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists
TW200637863A (en) Organic compounds
TW200738692A (en) New substituted glycinamides, process for their manufacture and use thereof as medicaments
MX2007007845A (es) Sulfonilpirrolidinas, metodo para producir las mismas y su uso como medicamento.
ATE484504T1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
DK1751093T3 (da) Substituerede cyklohexyleddikesyre-derivater
UA92733C2 (ru) Способ получения производных 4-(фенокси-5-метилпиримидин-4-илокси)пиперидин-1-карбоновой кислоты и родственных соединений
MX2009003257A (es) Procedimiento para la sintesis de derivados de fenoxi diaminopirimidina.
TW200635905A (en) Processes for producing 4-aminoquinazolines
DK1513800T3 (da) Benzoylureido-kanelsyrederivater, fremgangsmåde til deres anvendelse
ATE526312T1 (de) Verfahren zur herstellung von reinen 4- pyrrolidinophenylbenzyletherderivaten als maob- inhibitoren
ATE444964T1 (de) 5-pyridinyl-1-azabicycloä3.2.1üoctan-derivate, herstellungsverfahren und deren verwendung für therapeutika
ATE532516T1 (de) Verfahren zur synthese von glyt-1-hemmern
ATE388154T1 (de) Kristalline form von cefdinir-ammoniumsalz als zwischenprodukt für die herstellung von reinem cefdinir
TW200716555A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
DE602005013007D1 (de) Verfahren zur herstellung von lactonen
ATE473213T1 (de) Verfahren zur herstellung von phenyl-2- pyrimidinyl-ketonen und neuen zwischenprodukten daraus
MY139236A (en) 4-trifluoromethoxyphenoxybenzene-4' -sulfonic acids, process for their preparation and use in medicaments
BRPI0514248A (pt) compostos orgánicos
SG162815A1 (en) Process for preparing benzimidazole compounds
ATE488512T1 (de) Piperazinderivate als ccr3-hemmer
MX2009005324A (es) Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos.
WO2009009002A3 (en) Hydrogen chloride salt of a substituted 5-oxazol-2-yl-quinoline compound and a process for the production thereof
TW200716565A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1915375

Country of ref document: EP